Revvity Inc. (NYSE:RVTY) Given Average Rating of “Hold” by Brokerages

Revvity Inc. (NYSE:RVTY) has been assigned a consensus recommendation of “Hold” from the fourteen analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $107.7273.

Several equities analysts have issued reports on the stock. Wall Street Zen downgraded shares of Revvity from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Robert W. Baird set a $117.00 price objective on shares of Revvity in a research note on Wednesday, May 6th. Barclays upped their price objective on shares of Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Wolfe Research assumed coverage on shares of Revvity in a research note on Tuesday. They issued a “peer perform” rating for the company. Finally, Stifel Nicolaus decreased their price objective on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a research note on Wednesday, May 6th.

Institutional Investors Weigh In On Revvity

A number of institutional investors and hedge funds have recently made changes to their positions in RVTY. Ascentis Independent Advisors purchased a new stake in shares of Revvity in the first quarter valued at about $29,000. CYBER HORNET ETFs LLC purchased a new stake in shares of Revvity in the second quarter valued at about $32,000. Cromwell Holdings LLC raised its holdings in shares of Revvity by 141.4% in the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after buying an additional 198 shares during the last quarter. MUFG Securities EMEA plc purchased a new stake in shares of Revvity in the second quarter valued at about $34,000. Finally, SJS Investment Consulting Inc. raised its holdings in shares of Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after buying an additional 521 shares during the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Price Performance

Shares of NYSE:RVTY opened at $98.46 on Friday. Revvity has a 12 month low of $81.22 and a 12 month high of $118.30. The firm has a market capitalization of $10.98 billion, a P/E ratio of 47.11, a P/E/G ratio of 2.24 and a beta of 1.11. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.72 and a quick ratio of 1.41. The company’s fifty day moving average price is $93.40 and its 200 day moving average price is $97.49.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The company had revenue of $711.12 million during the quarter, compared to the consensus estimate of $704.07 million. During the same quarter in the prior year, the firm posted $1.01 earnings per share. Revvity’s revenue for the quarter was up 7.0% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. As a group, sell-side analysts predict that Revvity will post 5.25 earnings per share for the current fiscal year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Friday, July 17th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, July 17th. Revvity’s dividend payout ratio is presently 13.40%.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.